Kuecept Ltd is a specialist pharmaceutical contract research organisation supporting clients with the early phase development of low solubility, poorly bioavailable compounds. Our patented drug delivery technologies and formulation expertise in oral and parenteral dosage form design and development are used to fast track compounds through preclinical efficacy studies and toxicity testing and into clinic with robust, stable and improved performance products.
In parallel, our technologies can also be used to reformulate existing pharmaceutical, OTC or nutraceutical products to extend patent protection or create innovative new line extensions.
Formulations for low solubility, poorly bioavailable compounds
Kuecept's strength is the combination of highly skilled and experienced staff and a specific focus on developing enabling formulations for low solubility, poorly bioavailable compounds. Having worked in this area for a number of years, we have gained a unique expertise and know-how in this specialist field that guarantees our clients high quality and robust services during every stage of preclinical and early clinical phase drug development.
Formulation prototype development for clinical evaluation
As a seamless extension of your own R&D team, we work to understand your drug candidates and their intended use and then use our proven experience, drug delivery technologies and creativity to guide you through preclinical safety and efficacy studies and into formulation prototype development for clinical evaluation.
Our technologies are used to:
- Assess the development potential of poorly soluble compounds using our advanced drug profiling technologies
- Identify the most suitable route to improve drug solubility and bioavailability
- Design and develop appropriate formulation strategies to support preclinical safety and efficacy studies as well as accelerate entry into clinic (Fast in Man service)
- Improve sub-optimal release profiles by developing alternatives such as fast dissolving, controlled or modified / targeted release dosage forms
- Formulate APIs with complex physical or chemical characteristics such as low melting point, hygroscopic tendency or physically instability
- Reformulate existing pharmaceutical, OTC or nutraceutical products to extend patent protection or create innovative new line extensions
For more information on these services, please see the product list for more details.
Drug substance physicochemical profiling
Since inception, we have successfully partnered over 50 international customers on programs ranging from drug substance physicochemical profiling and lead compound selection through to developing enabling formulations to support clinical investigations. Our highly qualified and experienced staff have performed nearly 200 research studies on over 100 active materials and have successfully transferred many compounds into clinical studies.
Providing research to commercialisation of in house developed technologies
Based on previous experiences within the pharmaceutical industry, the founders of Kuecept recognised a need for developing new enabling technologies and processes to facilitate the rapid identification and production of soluble intermediates for poorly soluble compounds and which could be incorporated into a wide range of conventional oral and parenteral dosage forms for preclinical and clinical use.
In July 2007, funded solely by the existing shareholders, Synectix Pharmaceutical Solutions Ltd was incorporated to address these issues and started trading as a 100 % privately owned company. After nearly three years of rapid growth and having seen several technoloiges developed and implement in both preclinical and clinical trials, in Jan 2010 the company name was changed to Kuecept Ltd . This name change reflects the shift in focus of the business, from providing consultancy based support services to providing research to commercialisation of in house developed technologies for use in the production of high quality and improved performance dosage forms for pharmaceutical and biopharmaceutical actives.
Tredomen Business and Technology Centre
Research and Innovation Centre:
16/17 Station Close
To request a quote or to learn more about our drug delivery technologies and services, please contact: Dr Mark Saunders, development director on Tel: +44 (0) 845 084 0553 or e-mail: firstname.lastname@example.org.